## COO: The Cooper Companies, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.3% below STRENGTH zone (3.0-6.0%); PEG 2.15 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.3% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($78.33)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Albert White Bought 4.4% More Shares In Cooper Companies**
- Source: Simply Wall Street | 20251224T110826 | Bullish | Relevance: 100%
- Albert White, President of The Cooper Companies (NASDAQ:COO), recently purchased US$808k worth of shares, increasing his holding by 4.4%. This significant insider buy, valued at an average price of US$80.80 per share, suggests strong confidence in the company's future prospects. Insiders at Cooper Companies have been buying shares over the last year without selling, indicating a general trend of optimism.

**2. CooperCompanies appoints Walt Rosebrough to board in deal with Browning West**
- Source: Investing.com India | 20251223T132751 | Bullish | Relevance: 100%
- CooperCompanies (NASDAQ:COO) has appointed Walter "Walt" M. Rosebrough, Jr. as an independent director, effective January 3, 2026, following a cooperation agreement with Browning West, LP. Rosebrough, CEO Emeritus of STERIS plc, will join the Corporate Governance & Nominating Committee, with consideration for him to become Chair by the end of 2026. This move comes as CooperCompanies' stock has gained 20.6% over the past six months, reflecting recent financial outperformances and positive analyst revisions.

**3. Baldwin Wealth Partners LLC MA Sells 141,836 Shares of The Cooper Companies, Inc. $COO**
- Source: MarketBeat | 20251222T220748 | Somewhat-Bullish | Relevance: 100%
- Baldwin Wealth Partners LLC MA significantly reduced its stake in The Cooper Companies (NASDAQ:COO) by selling 141,836 shares, retaining 25,555 shares valued at $1.75 million. The Cooper Companies exceeded Q3 earnings and revenue expectations, and its board approved a $2.0 billion share buyback program. Meanwhile, institutional investors show mixed activity in their holdings of COO, and analysts have issued varied price targets for the stock.

**4. Voya Investment Management LLC Reduces Position in The Cooper Companies, Inc. $COO**
- Source: MarketBeat | 20251224T141118 | Somewhat-Bullish | Relevance: 100%
- Voya Investment Management LLC decreased its stake in The Cooper Companies, Inc. by 9.3% in Q3, now holding 130,167 shares valued at $8.9 million. This adjustment follows Cooper Companies' strong Q4 earnings, positive FY2026 guidance, and a $2.0 billion share buyback authorization, alongside a significant governance shift with new board appointments and activist investor involvement. Insider purchases also indicate confidence despite potential near-term uncertainty from the governance reset.

**5. CooperCompanies Appoints Walter M. Rosebrough, Jr. to its Board of Directors**
- Source: VisionMonday.com | 20251224T052618 | Bullish | Relevance: 100%
- CooperCompanies has appointed Walter M. Rosebrough, Jr. as an independent director, effective January 3, 2026, stemming from a cooperation agreement with investment firm Browning West, LP. Rosebrough, CEO emeritus of STERIS plc, will join the board's corporate governance and nominating committee, with serious consideration for him to become chair by the end of 2026. This move follows Browning West's criticism of Cooper's "underperformance" and desire for board-level change to optimize the business and enhance shareholder value.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 10, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Citigroup | $88 | $72 | +22% |
| 2025-12-08 | Morgan Stanley | $83 | $76 | +9% |
| 2025-12-08 | Goldman Sachs | $71 | $64 | +11% |
| 2025-12-05 | Stifel | $95 | $85 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Citigroup | main | Neutral |
| 2025-12-08 | Morgan Stanley | main | Equal-Weight |
| 2025-12-08 | Goldman Sachs | main | Sell |
| 2025-12-05 | Stifel | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 8 ($1.04M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.2% (-1.1%)
- Blackrock Inc.: 7.8% (-0.8%)
- Capital World Invest: 5.4% (+25.7%)
- T. Rowe Price Invest: 5.0% (+33.2%)
- State Street Corpora: 4.4% (-0.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 10 raises (avg +14%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.15 elevated, pricing in significant growth expectations. Analyst sentiment positive (10 raises, avg +14%). Insider buying signal ($1.0M), management confidence. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $16.4B |
| Beta | 1.05 |
| 52W Range | $61.78 - $100.24 |
| Short Interest | 4.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.15 |
| Forward P/E | 16.7 |
| Current P/E | 18.3 |
| YoY Growth | 9.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 3.0% to -1.3% (-4.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.3pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.29% (CS: 43) | Neutral |
| RSI_14 | 63.8 | Neutral |
| MACD Histogram | 0.01 | Bullish |
| vs SMA20 | 1.029x | Above |
| vs SMA50 | 1.096x | Above |
| vs SMA200 | 1.109x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $82.57
- **Stop Loss:** $78.33 (5.1% risk)
- **Target:** $86.81 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 283
- **Position Value:** $23,367.31
- **Portfolio %:** 23.37%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite supported by year-end positioning. VIX at cycle lows (13.47) and multiple sectors hitting 52-week highs indicate constructive sentiment, though breadth at 57.9% suggests selectivity remains important. Fed pause expectations and stable macro backdrop support risk assets.*

### Earnings

**Next:** 2026-03-05 (Est: $1.03)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.11 | $1.15 | +3.3% |
| 2025Q3 | $1.07 | $1.10 | +3.0% |
| 2025Q2 | $0.93 | $0.96 | +3.3% |
| 2025Q1 | $0.91 | $0.92 | +0.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*